NCT00673140

Brief Summary

Amyotrophic Lateral Sclerosis (ALS, sometimes called Lou Gehrig's s Disease, or Maladie de Charcot) is a progressive, usually fatal, neurodegenerative disease caused by the degeneration of motor neurons, the nerve cells in the central nervous system that control voluntary muscle movement. This study will investigate the use of far infrared radiation for the control, management and treatment of ALS.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
7

participants targeted

Target at below P25 for phase_1

Timeline
Completed

Started May 2008

Typical duration for phase_1

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2008

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

May 6, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

May 7, 2008

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2010

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2010

Completed
Last Updated

August 17, 2009

Status Verified

August 1, 2009

Enrollment Period

2 years

First QC Date

May 6, 2008

Last Update Submit

August 14, 2009

Conditions

Amyotrophic Lateral Sclerosis

Keywords

ALS (Amyotrophic Lateral Sclerosis)Amyotrophic Lateral Sclerosis With DementiaAmyotrophic Lateral Sclerosis, Guam FormDementia With Amyotrophic Lateral SclerosisGehrig's DiseaseGuam Form of Amyotrophic Lateral SclerosisLou Gehrig Disease

Outcome Measures

Primary Outcomes (1)

  • Therapy for ALS

    2 years

Secondary Outcomes (1)

  • Rehabilitation of ALS patients

    2 Years

Study Arms (1)

1

EXPERIMENTAL

Radiation: Far Infrared Radiation (5μm to 20μm wavelength)

Radiation: Far Infrared Radiation (5μm to 20μm wavelength)Radiation: Far infrared radiation

Interventions

Far Infrared Radiation (5μm to 20μm wavelength)RADIATION

Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.

Also known as: Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
1
Far infrared radiationRADIATION

Far infrared radiation at a frequency of 5 microns to 20 microns for 30 to 40 minutes per session.

1

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with ALS

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Centre for Incurable Diseases

Toronto, Ontario, M4V 1L5, Canada

Location

MeSH Terms

Conditions

Amyotrophic Lateral Sclerosis

Condition Hierarchy (Ancestors)

Spinal Cord DiseasesCentral Nervous System DiseasesNervous System DiseasesMotor Neuron DiseaseNeurodegenerative DiseasesTDP-43 ProteinopathiesNeuromuscular DiseasesProteostasis DeficienciesMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Ken Nedd, M.D.

    GAAD Medical Research Institute Inc.

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

May 6, 2008

First Posted

May 7, 2008

Study Start

May 1, 2008

Primary Completion

May 1, 2010

Study Completion

June 1, 2010

Last Updated

August 17, 2009

Record last verified: 2009-08

Locations

CA(1)